NBM-BMX is under clinical development by NatureWise Biotech & Medicals and currently in Phase I for Glioblastoma Multiforme (GBM). According to GlobalData, Phase I drugs for Glioblastoma Multiforme (GBM) have an 82% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how NBM-BMX’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
NBM-BMX overview
NBM-01 (NBMTBMXOS-01) is under development for the treatment of advanced solid tumors, glioblastoma multiforme. It is administered through oral route as a capsule. The drug candidate is a new chemical entity and targets histone deacetylase 8 (HDAC8). It was under development for the treatment of pancreatic cancer, colorectal cancer and for improving cognitive functions such as learning and memory.
It was under development for the treatment of Alzheimer's disease.
NatureWise Biotech & Medicals overview
NatureWise Biotech & Medicals (NBM) is a drug development company that develops botanical drug and small molecule therapies. The company’s PPLs Taiwan Green Propolis product increase the survival of neural stem cells, enhance the outgrowth of neurites and modulate blood sugar. NBM’s pipeline products include NBM-BMX for the treatment of cancer and alzheimer’s disease and NBM-1001 for the treatment of retinopathy. Its red yeast products comprise lipocol and lipocol forte, among others. NBM conducts biotech drug development center program and develops Chinese medicine for brain cancer and anticancer drug HDAC inhibitor. The company offers its products to the healthcare sector. NBM is headquartered in Taipei, Taiwan.
For a complete picture of NBM-BMX’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
